What is GYRE's dilution risk score?

GYRE has a latest available DilutionScore record of 38/100, categorized as medium dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for GYRE, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for GYRE?

DilutionWatch tracks 25 SEC filing types for GYRE including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect GYRE shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For GYRE, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for GYRE tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for GYRE. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

GYRE Dilution Risk Score: 38/100 (MEDIUM)

Score Breakdown

📋 Offering Ability

52

💰Cash Runway—

📊 Float Risk

80

⚠️ Warrant Exposure

15

🔄 Convertible Debt

15

Dilution Forecast

☀️

Clear

No significant dilution signals

model est. 0%

No significant dilution signals detected for GYRE.

🔔 Track GYRE — Get forecast alerts →

Market Data

Market Cap$573.44M

Shares Outstanding111.51M

Float21.28M

Cash$57.34M

Debt$620.0K

Short InterestN/A

Institutional Holdings

QoQ: ↑ 34.1% shares (2026Q1 vs prior)

57 institutional holders · 4.54M shares

#1 VANGUARD CAPITAL MANAGEMENT LLC 1.97M shares

#2 BlackRock, Inc. 758.6K shares

#3 GEODE CAPITAL MANAGEMENT, LLC 431.4K shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest1.82M

Days to Cover37.4

% of Float8.6%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2026-06-30

xbrl XBRL CONVERTIBLE 2018-12-31

Form 4 INSIDER TRANSACTION 2026-08-03

8-K 8K EVENT 2026-05-04

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual GYRE Dilution Snapshot

Gyre Therapeutics, Inc. (GYRE) has a DilutionScore of 38/100, rated Medium dilution risk. Score date: August 28, 2026.

Stored outstanding warrants: 2.1M.
Recent SEC activity tracked for GYRE: Form 4 on 2026-08-03; Form 4 on 2026-08-03; xbrl on 2026-06-30.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.